These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 33615756)

  • 1.
    Dalmau J; Dalakas MC; Kolson DL; Paul F; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31831570
    [No Abstract]   [Full Text] [Related]  

  • 2. Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Reese SW; Cone E; Marchese M; Garcia B; Chou W; Ayub A; Kilbridge K; Weinhouse G; Trinh QD
    Lung; 2021 Apr; 199(2):199-211. PubMed ID: 33616727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen.
    Pous A; Izquierdo C; Cucurull M; Sánchez S; Lezcano C; Domenech M; Llobera L; Plaja A; Moran T
    Transl Lung Cancer Res; 2021 Apr; 10(4):1917-1923. PubMed ID: 34012801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature.
    Janssen JBE; Leow TYS; Herbschleb KH; Gijtenbeek JMM; Boers-Sonderen MJ; Gerritsen WR; Westdorp H
    J Immunother; 2021 Sep; 44(7):276-282. PubMed ID: 33758147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Ohnishi T; Sagara H
    Curr Oncol; 2021 Feb; 28(2):1094-1113. PubMed ID: 33673470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
    Alkrekshi A; Tamaskar I
    Oncologist; 2021 May; 26(5):e827-e830. PubMed ID: 33655663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS.
    Chen C; Chen T; Liang J; Guo X; Xu J; Zheng Y; Guo Z; Chi L; Wei L; Chen X; Ye X; He J
    Front Pharmacol; 2021; 12():616505. PubMed ID: 33643048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study.
    Shimozaki K; Hirata K; Horie S; Chida A; Tsugaru K; Hayashi Y; Kawasaki K; Miyanaga R; Hayashi H; Mizuno R; Funakoshi T; Hosoe N; Hamamoto Y; Kanai T
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33803735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase.
    Noseda R; Bonaldo G; Motola D; Stathis A; Ceschi A
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor-induced diarrhea and colitis: an overview.
    Zoghbi M; Burk KJ; Haroun E; Saade M; Carreras MTC
    Support Care Cancer; 2024 Sep; 32(10):680. PubMed ID: 39311981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.
    Del Gaudio A; Di Vincenzo F; Petito V; Giustiniani MC; Gasbarrini A; Scaldaferri F; Lopetuso LR
    Inflamm Bowel Dis; 2024 Jun; 30(6):1018-1031. PubMed ID: 37801695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal injury induced by immunomodulators: A review article.
    Zhang P; Mao R; Zhang C; Qiu Y; Chen M
    Therap Adv Gastroenterol; 2023; 16():17562848231158549. PubMed ID: 37113189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System.
    Yu Z; Zhu H; Chen H; Zhu L; Liao X
    J Pharm Pharm Sci; 2023; 26():11235. PubMed ID: 36942297
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor immune checkpoints and their associated inhibitors.
    Gao Z; Ling X; Shi C; Wang Y; Lin A
    J Zhejiang Univ Sci B; 2022 Oct; 23(10):823-843. PubMed ID: 36226537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database.
    Huang S; Bai X; Fang T; Guo Y; Zheng K; Lin X
    J Zhejiang Univ Sci B; 2021 Feb; 22(2):156-164. PubMed ID: 33615756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019.
    Hu F; Ye X; Zhai Y; Xu J; Guo X; Guo Z; Zhou X; Ruan Y; Zhuang Y; He J
    Immunotherapy; 2020 May; 12(7):531-540. PubMed ID: 32456497
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.